Expands Pfizer’s access to lipid nanoparticle (LNP) formulation technology, offering a strong strategic fit with Pfizer’s mRNA strategy Pfizer gains option to license Acuitas’ LNP technology for up to ...
Scientists at the Icahn School of Medicine at Mount Sinai have developed a lipid nanoparticle system capable of delivering messenger RNA (mRNA) to the brain via intravenous injection, a challenge that ...
Certest Pharma specializes in advanced lipid nanoparticle technology, focusing on the development of effective and targeted LNPs for next-generation medicines. Certest’s licensable technology includes ...
CHARLOTTETOWN, Prince Edward Island & VANCOUVER, British Columbia--(BUSINESS WIRE)--BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service ...
Driven by the increasing need for novel LNP formulation, along with the ongoing advancements in the LNP technology, the lipid nanoparticle manufacturing market is anticipated to grow at a CAGR of 11.8 ...
The Nanoparticle Contract Manufacturing market offers opportunities in pharmaceuticals, biotech, and advanced materials, driven by demand for complex nanoparticle formulations. CMOs enhance ...
insights from industryYoann LefeuvreDirector of Product ManagementMicrotrac In this interview, AZoNano speaks with Yoann Lefeuvre, Director of Product Management at Microtrac. Yoann discusses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results